Dataset Information

ImmunoPET provides a novel way to visualize the CD103⁺ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have made significant progress in oncotherapy improving survival of patients. However, the benefits are limited to only a small subgroup of patients who could achieve durable responses. Early prediction of response may enable treatment optimization and patient stratification. Therefore, developing appropriate biomarkers is critical to monitoring efficacy and assessing patient response to ICIs.

Main body

Herein, we first introduce a new potential biomarker, CD103, expressed on tissue-resident memory T cells, and discuss the potential application of CD103 PET imaging in predicting immune checkpoint inhibitor treatment. In addition, we describe the current targets of ImmunoPET and compare these targets with CD103. To assess the ben

SUBMITTER: Fan X

PROVIDER: S-EPMC10769965 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

ImmunoPET provides a novel way to visualize the CD103⁺ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.

Background

Main body

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.

Background

Main body

OmicsDI is part of the ELIXIR infrastructure

Tweets

ImmunoPET provides a novel way to visualize the CD103⁺ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.